Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy

Basit Öğe Kaydı
dc.authoridDogu, Mehmet Hilmi/0000-0001-7237-2637
dc.authoridbilen, yusuf/0000-0003-2387-4010
dc.authoridYILMAZ, Mehmet/0000-0002-5710-5263
dc.authoridGURKAN, EMEL/0000-0002-3060-4054
dc.authorwosidKorkmaz, Serdal/IST-3736-2023
dc.authorwosidDogu, Mehmet Hilmi/W-2255-2017
dc.authorwosidbilen, yusuf/ABH-9885-2022
dc.authorwosidYILMAZ, Mehmet/HKM-4739-2023
dc.authorwosidGURKAN, EMEL/E-8808-2018
dc.contributor.authorHacioglu, Sibel
dc.contributor.authorBilen, Yusuf
dc.contributor.authorEser, Ali
dc.contributor.authorSivgin, Serdar
dc.contributor.authorGurkan, Emel
dc.contributor.authorYildirim, Rahsan
dc.contributor.authorAydogdu, Ismet
dc.date.accessioned2024-08-04T20:41:27Z
dc.date.available2024-08-04T20:41:27Z
dc.date.issued2015
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIn this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy ( 95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. Copyright (C) 2014 John Wiley & Sons, Ltd.en_US
dc.identifier.doi10.1002/hon.2177
dc.identifier.endpage198en_US
dc.identifier.issn0278-0232
dc.identifier.issn1099-1069
dc.identifier.issue4en_US
dc.identifier.pmid25393847en_US
dc.identifier.scopus2-s2.0-84954543319en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage192en_US
dc.identifier.urihttps://doi.org/10.1002/hon.2177
dc.identifier.urihttps://hdl.handle.net/11616/97130
dc.identifier.volume33en_US
dc.identifier.wosWOS:000368248400011en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofHematological Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecthairy cell leukemiaen_US
dc.subjectTurkeyen_US
dc.subjecttreatmenten_US
dc.subjectcladribinen_US
dc.subjectsurvivalen_US
dc.titleMulticenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu